Kezar Life Sciences, Inc. (KZR) Tops Q3 EPS by 4c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7 million versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
• ICON plc (ICLR) PT Raised to $150 at BofA Securities